LENVATINIB

Tracking # 20-810387

$99999.00

There are no ratings for this course

Learn more

Educator STATPEARLS PUBLISHING, LLC

CE Broker Reporting Reported automatically

Method Computer-Based Training

Course overview

LENVATINIB IS FDA APPROVED FOR THE TREATMENT OF RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (DTC), UNRESECTABLE OR ADVANCED HEPATOCELLULAR CARCINOMA (HCC), AND ADVANCED RENAL CELL CARCINOMA (RCC). IT IS A MULTIPLE RECEPTOR TYROSINE KINASE INHIBITOR THAT DEMONSTRATES POTENT ANTIANGIOGENIC PROPERTIES. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS PERTINENT TO MEMBERS OF THE INTERPROFESSIONAL TEAM IN THE MANAGEMENT OF PATIENTS WITH RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (DTC), UNRESECTABLE OR ADVANCED HEPATOCELLULAR CARCINOMA (HCC), AND ADVANCED RENAL CELL CARCINOMA (RCC).

Subject areas

This course counts toward the state boards and subject areas below.

Bahamas Medical Council

Specialty Medical Practitioner

1h General Medicine

Louisiana State Board of Medical Examiners - Physicians & Surgeons

Physician & Surgeon

1h Category I CME

Mississippi State Board of Medical Licensure

Medical Doctor

1h AMA Category I

Physician Assistant

1h AMA Category I

State Medical Board of Ohio

Doctor of Medicine

1h AMA Category I